drugset / Trial / NCT04693715

Safety of RNS60 in Large Vessel Occlusion Stroke Patients Undergoing Endovascular Thrombectomy

NCT04693715

Phase 2 Completed 83 enrolled Revalesio Corporation
RandomizedParallel-groupTriple-blindTreatment

Summary

A Phase II, randomized, blinded, placebo-controlled, parallel group study with patients experiencing a large vessel occlusion acute ischemic stroke who are selected for endovascular revascularization. Participants will be given a 48 h infusion of either 0.5 mL/kg/h RNS60 (up to a maximum of 65 mL/h), 1.0 mL/kg/h RNS60 (up to a maximum of 130 mL/h), or 1.0 mL/kg/h (up to a maximum of 130 mL/h) placebo (normal saline) starting within 30 minutes of consent after confirmation of candidacy for endovascular thrombectomy.

Timeline

Start
2021-07-07
Primary completion
2023-11-08
Completion
2023-11-08

Drugs

EvaluationDrugModalityDoseRoute
Subject RNS60 Other / unclassified 0.5 unknown
Subject RNS60 Other / unclassified 1 unknown

Indications